Noa Biran
Division of Hematology and Oncology · Hackensack Meridian Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Noa Biran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:08 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05493618 · Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.Hackensack Meridian Health · withdrawn · Multiple Myeloma, Refractory · principal investigator
- Ph1/Ph2NCT05199311 · Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaHackensack Meridian Health · suspended · Multiple Myeloma · principal investigator
- Ph2NCT04700176 · A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple MyelomaHackensack Meridian Health · terminated · Multiple Myeloma · principal investigator
- Ph2NCT04661137 · A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaHackensack Meridian Health · recruiting · Multiple Myeloma · principal investigator
- Ph2NCT02906332 · Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)Hackensack Meridian Health · terminated · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:08 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.Br J Cancer · 202240 citationsRCR 2.7
- Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.JCI Insight · 202133 citationsRCR 1.7
- Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.Am J Hematol · 202127 citationsRCR 1.4
- Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.Nat Cancer · 202421 citationsRCR 2.2
- Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation.Transplant Cell Ther · 202116 citationsRCR 0.7
- Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.BMC Cancer · 202114 citationsRCR 0.7
- Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study.Am J Hematol · 201913 citationsRCR 0.4
- A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.Biol Blood Marrow Transplant · 201611 citationsRCR 0.3
- A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.Br J Haematol · 201711 citationsRCR 0.3
- 11 citationsRCR 0.5